Amgen Inc.
AMGN
Classificação em ações
#71
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California,... Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
Preço da ação
$436.87
Valor de mercado
$236.19B
Variação (1 dia)
2.81%
Variação (1 ano)
44.02%
País
US
Negociar Amgen Inc. (AMGN)
Categoria
Healthcare
Rácio P/E de Amgen Inc. (AMGN)
Rácio P/E em October 2026 TTM: 26.27
De acordo com os últimos relatórios financeiros e o preço das ações da Amgen Inc., o rácio P/E atual (TTM) é 26.27. No final de 2024, a empresa tinha um P/E de 34.48.
Histórico do rácio P/E da Amgen Inc. de 2000 a 2026
Rácio P/E no final de cada ano
| Ano | Índice P/E | Alterar |
|---|---|---|
| 2026 (TTM) | 26.27 | 15.02% |
| 2025 | 22.84 | -33.76% |
| 2024 | 34.48 | 50.28% |
| 2023 | 22.94 | 6.37% |
| 2022 | 21.57 | -0.89% |
| 2021 | 21.76 | 17.32% |
| 2020 | 18.55 | -0.27% |
| 2019 | 18.60 | 21.32% |
| 2018 | 15.33 | -76.14% |
| 2017 | 64.23 | 353.55% |
| 2016 | 14.16 | -20.13% |
| 2015 | 17.73 | -24.35% |
| 2014 | 23.44 | 38.64% |
| 2013 | 16.91 | 9.96% |
| 2012 | 15.38 | -2.55% |
| 2011 | 15.78 | 38.52% |
| 2010 | 11.39 | -8.74% |
| 2009 | 12.48 | -15.25% |
| 2008 | 14.73 | -10.12% |
| 2007 | 16.38 | -39.83% |
| 2006 | 27.23 | 2.64% |
| 2005 | 26.53 | -23.11% |
| 2004 | 34.50 | -2.04% |
| 2003 | 35.22 | -187.92% |
| 2002 | -40.06 | -176.02% |
| 2001 | 52.70 | -8.86% |
| 2000 | 57.82 | 0.00% |
Rácio P/E para empresas semelhantes ou concorrentes
| Empresa | Rácio P/E | Diferença do rácio P/E | País |
|---|---|---|---|
| 40.53 | 54.27% |
US
|
|
| 38.50 | 46.53% |
US
|
|
| 79.88 | 204.06% |
US
|
|
| 116.96 | 345.20% |
US
|
|
| 22.25 | -15.31% |
CH
|
Como interpretar um P/E Ratio?
O rácio Preço/Lucro (P/E) mede a relação entre o preço da ação de uma empresa e o lucro por ação.
Um P/E baixo mas positivo representa uma empresa com altos lucros face à sua valorização atual e pode estar subvalorizada. Um P/E negativo elevado (perto de 0) representa perdas significativas.
Empresas com P/E acima de 30 ou negativo são geralmente vistas como "ações de crescimento", significando que os investidores esperam crescimento ou rentabilidade futura.
Empresas com P/E positivo inferior a 10 são geralmente consideradas "ações de valor", ou seja, já são muito lucrativas mas com pouco potencial de crescimento.